Brokers Set Expectations for CalciMedica Q1 Earnings

CalciMedica Inc. (NASDAQ:CALC) – Equities researchers at HC Wainwright issued their Q1 2026 EPS estimates for CalciMedica in a research report issued on Tuesday, March 3rd. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings of ($0.31) per share for the quarter. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for CalciMedica’s current full-year earnings is ($2.21) per share. HC Wainwright also issued estimates for CalciMedica’s Q2 2026 earnings at ($0.33) EPS, Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.43) EPS, FY2026 earnings at ($1.45) EPS, FY2027 earnings at ($0.86) EPS and FY2028 earnings at ($0.98) EPS.

A number of other equities analysts have also recently commented on CALC. Oppenheimer cut their target price on shares of CalciMedica from $20.00 to $10.00 and set an “outperform” rating on the stock in a report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of CalciMedica in a research report on Wednesday, January 21st. Finally, Wall Street Zen raised shares of CalciMedica to a “sell” rating in a report on Saturday, January 17th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, CalciMedica currently has a consensus rating of “Hold” and an average price target of $13.00.

CalciMedica Trading Up 10.0%

NASDAQ:CALC opened at $0.73 on Friday. The company has a market capitalization of $11.44 million, a PE ratio of -0.45 and a beta of 0.60. CalciMedica has a 52-week low of $0.46 and a 52-week high of $7.20. The stock’s 50 day moving average price is $2.86 and its 200 day moving average price is $3.33. The company has a quick ratio of 4.04, a current ratio of 3.58 and a debt-to-equity ratio of 1.39.

CalciMedica (NASDAQ:CALC) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.69) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On CalciMedica

Hedge funds have recently added to or reduced their stakes in the company. Sound View Wealth Advisors Group LLC acquired a new position in CalciMedica during the 2nd quarter worth approximately $32,000. Cetera Investment Advisers raised its position in CalciMedica by 33.1% in the second quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock worth $58,000 after acquiring an additional 9,045 shares in the last quarter. Atria Investments Inc lifted its holdings in CalciMedica by 20.0% in the second quarter. Atria Investments Inc now owns 44,700 shares of the company’s stock valued at $72,000 after acquiring an additional 7,436 shares during the period. Jane Street Group LLC acquired a new position in shares of CalciMedica during the 4th quarter worth $127,000. Finally, Envestnet Asset Management Inc. increased its holdings in shares of CalciMedica by 58.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after purchasing an additional 34,386 shares in the last quarter.

Key Headlines Impacting CalciMedica

Here are the key news stories impacting CalciMedica this week:

• Positive Sentiment: HC Wainwright raised its FY2027 and FY2028 EPS forecasts (FY2027 to $(0.86) from $(1.06); FY2028 to $(0.98) from $(1.20)), reducing projected losses in later years — a constructive signal for long‑term outlook. HC Wainwright estimates
• Neutral Sentiment: HC Wainwright kept a “Neutral” rating while publishing detailed quarterly EPS estimates for 2026 (Q1 $(0.31), Q2 $(0.33), Q3 $(0.37), Q4 $(0.43)) and revised FY2026 to $(1.45) — the near‑term outlook remains loss‑making, so catalyst timing is unclear. HC Wainwright estimates
• Neutral Sentiment: Short‑interest filings reported 0 shares outstanding short and a 0.0 days‑to‑cover figure — described as a “large increase” in the feed but numerically inconsistent (NaN/0). This looks like a data/reporting anomaly rather than a confirmed short squeeze or heavy shorting pressure. No direct link available.
• Negative Sentiment: Oppenheimer cut its price target sharply from $20 to $10 (while keeping an “Outperform” rating), which is a notable downward revision of expected upside and may weigh on sentiment despite the retained bullish rating. Oppenheimer price target cut Additional coverage

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.